Bronkopulmoner Displaziye Güncel Yaklaşım

Year 2012, Volume: 6 Issue: 3, 185 - 192, 01.06.2012

Arzu Akdağ Nurdan Uraş Uğur Dilmen

Abstract

Yenidoğan bakım kalitesinin artması çok küçük prematüre bebeklerin yaşatılmasına olanak sağlamış olmakla birlikte bu bebeklerde “Yeni Bronkopulmoner Displazi” (BPD) olarak tanımlanan klinik, radyolojik ve histopatolojik bulguları daha hafif seyirli olan BPD nin yeni bir şekli ortaya çıkmıştır. Yeni BPD şekli, esas olarak akciğer gelişiminde duraksama ve pulmoner fonksiyonların bozulması ile ilişkilidir. Akciğer gelişiminin kanaliküler ve sakküler fazında doğan prematüre yenidoğanlarda çeşitli risk faktörlerinin etkisiyle alveol ve damar gelişimi sekteye uğramakta böylece alveolar ve kapiller hipoplazi ortaya çıkmaktadır. Surfaktan yetersizliği, yenidoğanın ventilasyonu, oksijen tedavisi, reaktif oksijen ürünleri, akciğer ödemi, fetal ve neonatal infeksiyonlar ve akciğer damar gelişiminde bozulma ile bazı antenatal etmenler akciğer hasarlanmasından sorumlu tutulmaktadır. Bu yazıda prematüre yenidoğanlardaki akciğer hasar mekanizmaları, yeni BPD tanımı, klasik BPD tablosundan farklılıkları, BPD den korunmaya yönelik güncel yaklaşımlar incelenmiştir.

Keywords

Bronkopulmoner displazi, yenidoğan, prematürite

CURRENT APPROACH TO BRONCHOPULMONARY DYSPLASIA

Abstract

Improvements in antenatal and neonatal care have resulted in an increase in the survival of very preterm infants, whereas new form of Bronchopulmonary displasia (BPD) that has mild clinical course, radiological, and histopathological findings has occurred in these babies.. This new form of BPD is mainly related with a disruption of lung organogenesis and impaired pulmonary function. In premature infants born at the intersection of the canalicular and saccular phases of lung development, alveolar and capiller development are inhibited following exposure to the noxious effects of different risk factors. As a result, alveolar and capiller hypoplasia occur in these premature babies. These risk factors include surfactant deficiency, neonatal ventilation, oxygen therapy, reactive oxygen species, lung oedema, fetal and neonatal infections, disruption of vasculogenesis, and some antenatal factors that dysregulate subsequent lung development. In this article, mechanisms of lung injury in the preterm infants, the definition of new BPD, the difference between ‘‘old’’ and ‘’new’’ BPD, and the current approaches to prevent BPD have been reviewed

Keywords

Bronchopulmonary dysplasia, newborn, prematurity

References

• Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease follo- wing respirator therapy of hyaline-membrane disease. Bronchopul- monary dysplasia N Engl J Med 1967;276(7):357–68.
• Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neo- natol 2003;8(1):63-71.
• Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Ban- calari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996;128(4):470-8.
• Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163(7):1723-9.
• Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fa- naroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116(6):1353–60.
• Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003;8(1):73–81.
• Haataja R, Rova M, Marttila R, Hallman M. TDT analysis of sur- factant protein B gene intron 4 deletion variants in Finnish preterm infants with bronchopulmonary dysplasia. ATS 2005 International Conference, 2005, May 20–25
• Arch Dis Child Fetal Neonatal Ed 1999;81(3):162-7.
• Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT. High-frequency oscillatory ventilation versus con- ventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med 2002;347(9):643–52.
• Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002;347(9):633–42.
• Marlow N, Greenough A, Peacock JL, Marston L, Limb ES, John- son AH, et al. Randomised trial of high frequency oscillatory ven- tilation or conventional ventilation in babies of gestational age 28 weeks or less: respiratory and neurological outcomes at 2 years. Arch Dis Child Fetal Neonatal Ed 2006;91(5):320–6.
• Wheeler K, Klingenberg C, McCallion N, Morley CJ, Davis PG.Volume-targeted versus pressure-limited ventilation in the neo- nate. Cochrane Database Syst Rev 2010;11:CD003666.
• Lassus P, Turanlahti M, Heikkila P, Andersson LC, Nupponen I, Sarnesto A, et al. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in per- sistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001;164(10 PT 1):1981-7.
• Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Mont- gomery G, Grover TR, et al. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol 2005;289(4):529–35.
• Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279(3):600–7.
• Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physi- ol Lung Cell Mol Physiol 2002;283(3):555-62.
• Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsel- la JP, et al. Inhaled nitric oxide attenuates pulmonary hypertensi- on and improves lung growth in infant rats after neonatal treat- ment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004;287(2):344–51.
• Coalson JJ, Winter V, deLemos RA. Decreased alveolarization in baboon survivors with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1995;152(2):640-6.
• Wilborn AM, Evers LB, Canada AT. Oxygen toxicity to the deve- loping lung of the mouse: role of reactive oxygen species. Pediatr Res 1996;40(2):225–32.
• Van Tuyl M, Liu J,Wang J, Kuliszewski M, Tibboel D, Post M. Role of oxygen and vascular development in epithelial branching morphogenesis of the developing mouse lung. Am J Physiol Lung Cell Mol Physiol 2005;288(1):167–78.
• Allison BJ, Crossley KJ, Flecknoe SJ, Davis PG, Morley CJ, Hoo- per SB. Ventilation and oxygen: dose-related effects of oxygen on ventilation-induced lung injury. Pediatr Res 2010;67(3):238-43.
• Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen- saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003;349(10):959-67.
• Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short-and long-term morbidity in very low birth we- ight infants. Cochrane Database Syst Rev 2007;(4) CD000501.
• Wardle SP, Hughes A, Chen S, Shaw NJ. Randomised control- led trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2001;84(1):9-13.
• Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, et al. Vitamin A supplementation for extremely-lowbirth in- fants. N Engl J Med 1999;340(25):1962-8.
• Suresh G, Davis JM, Soll R. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated infants. Cochrane Database Syst Rev 2001;(1):CD001968.
• Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Schaeffer H, Fri- edman A. Prevention of bronchopulmonary dysplasia by administ- ration of bovine superoxide dismutase in preterm infants with res- piratory distress syndrome. J Pediatr 1984;105(5):781–5.
• Davis JM, Rosenfeld WN, Richter SE, Parad MR, Gewolb IH, Spitzer AR, et al. Safety and pharmacokinetics of multiple do- ses of recombinant human CuZn superoxide dismutase administe- red intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997;100(1):24–30.
• Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, et al. N-Acetylcysteine does not prevent bronchopulmonarydy- splasia in immature infants: a randomized controlled trial. J Pediatr 2003;143(6):713–9.
• Jobe AH. Antenatal factors and the development of bronchopulmo- nary dysplasia. Semin Neonatol 2003;8(1):9–17.
• Kallapur SG, Kramer BW, Moss TJ, Newnham JP, Jobe AH, Ikega- mi M, et al. Maternal glucocorticoids increase endotoxin-induced lung inflammation in preterm lambs. Am J Physiol Lung Cell Mol Physiol 2003;284(4):633–42.
• Willet KE, Jobe AH, Ikegami M, Newnham J, Brennan S, Sly PD. Antenatal endotoxin and glucocorticoid effects on lung morpho- metry in preterm lambs. Pediatr Res 2000;48(6):782–8.
• Van Marter LJ, Leviton A, Allred EN, Pagano M, Kuban KC. Hydration during the first days of life and the risk of bronc- hopulmonary dysplasia in low birth weight infants. J Pediatr 1990;116(6):942-9.
• Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 1980;38(1-2):96-105.
• Varsila E, Hallman M, Venge P, Andersson S. Closure of patent ductus arteriosus decreases pulmonary myeloperoxidase in pre- mature infants with respiratory distress syndrome. Biol Neonate 1995;67(3):167-71.